Literature DB >> 11564370

Neonatal lupus: clinical features, therapy, and pathogenesis.

L A Lee1.   

Abstract

Neonatal lupus is a disease characterized by one or more of the following findings: congenital heart block, cardiomyopathy, cutaneous lupus lesions, hepatobiliary disease, and thrombocytopenia. Accumulating evidence indicates that the disease is probably caused by maternal autoantibodies, particularly autoantibodies of the Ro family. While often initially asymptomatic, mothers tend to develop symptoms of connective tissue disease. This review discusses the recent advances in the understanding of neonatal lupus, its clinical features, therapy, and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564370     DOI: 10.1007/s11926-996-0009-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  38 in total

1.  Management with a staged approach of the premature hydropic fetus due to complete congenital heart block.

Authors:  E Deloof; H Devlieger; R Van Hoestenberghe; K Van den berghe; W Daenen; M Gewillig
Journal:  Eur J Pediatr       Date:  1997-07       Impact factor: 3.183

2.  Delayed dilated cardiomyopathy as a manifestation of neonatal lupus: case reports, autoantibody analysis, and management.

Authors:  E Taylor-Albert; M Reichlin; W H Toews; E D Overholt; L A Lee
Journal:  Pediatrics       Date:  1997-05       Impact factor: 7.124

3.  Induction of in vitro heart block is not restricted to affinity purified anti-52 kDa Ro/SSA antibody from mothers of children with neonatal lupus.

Authors:  V S Viana; S Garcia; J H Nascimento; K B Elkon; N Brot; A C Campos de Carvalho; E Bonfá
Journal:  Lupus       Date:  1998       Impact factor: 2.911

4.  Concentration of autoantibodies to native 60-kd Ro/SS-A and denatured 52-kd Ro/SS-A in eluates from the heart of a child who died with congenital complete heart block.

Authors:  M Reichlin; A Brucato; M B Frank; P J Maddison; V R McCubbin; M Wolfson-Reichlin; L A Lee
Journal:  Arthritis Rheum       Date:  1994-11

5.  Neonatal lupus erythematosus: results of maternal corticosteroid therapy.

Authors:  K Shinohara; S Miyagawa; T Fujita; T Aono; K Kidoguchi
Journal:  Obstet Gynecol       Date:  1999-06       Impact factor: 7.661

6.  The clinical spectrum of anti-Ro-positive cutaneous neonatal lupus erythematosus.

Authors:  W L Weston; J G Morelli; L A Lee
Journal:  J Am Acad Dermatol       Date:  1999-05       Impact factor: 11.527

Review 7.  Neonatal lupus.

Authors:  J P Buyon
Journal:  Curr Opin Rheumatol       Date:  1996-09       Impact factor: 5.006

8.  Autoantibodies directed against sicca syndrome antigens in the neonatal lupus syndrome.

Authors:  H L Franco; W L Weston; C Peebles; S L Forstot; P Phanuphak
Journal:  J Am Acad Dermatol       Date:  1981-01       Impact factor: 11.527

9.  Serum and immunoglobulin G from the mother of a child with congenital heart block induce conduction abnormalities and inhibit L-type calcium channels in a rat heart model.

Authors:  M Boutjdir; L Chen; Z H Zhang; C E Tseng; N El-Sherif; J P Buyon
Journal:  Pediatr Res       Date:  1998-07       Impact factor: 3.756

10.  Autoantibodies of neonatal lupus erythematosus.

Authors:  L A Lee; M B Frank; V R McCubbin; M Reichlin
Journal:  J Invest Dermatol       Date:  1994-06       Impact factor: 8.551

View more
  3 in total

1.  A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen.

Authors:  Dahai Xue; Hong Shi; James D Smith; Xinguo Chen; Dennis A Noe; Tommy Cedervall; Derek D Yang; Elizabeth Eynon; Douglas E Brash; Michael Kashgarian; Richard A Flavell; Sandra L Wolin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-03       Impact factor: 11.205

Review 2.  Neonatal lupus: clinical features and management.

Authors:  Lela A Lee
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 3.  The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity.

Authors:  Xinguo Chen; Sandra L Wolin
Journal:  J Mol Med (Berl)       Date:  2004-04       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.